Brief: Revive Therapeutics Says First Patient Enrolled For Psilocybin Clinical Study For Methamphetamine Use Disorder
28/03/2023 15:27
March 28 (Reuters) - Revive Therapeutics Ltd RVV.CD :
* REVIVE THERAPEUTICS PROVIDES UPDATE ON PSILOCYBIN CLINICAL
STUDY
FOR METHAMPHETAMINE USE DISORDER
* STUDY HAS ENROLLED ITS FIRST PATIENT AND INITIAL RESULTS
ARE
EXPECTED IN Q3-2023
Source text for Eikon: ID:nGNX3LWQms
Further company coverage: RVV.CD
((Reutersbriefs@thomsonreuters.com;))
Recent news on Revive Therapeutics
See all newsBrief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Provides Update Of Key Nerve Agent Countermeasure Study
Brief: Revive Therapeutics Announces Closing Of Second Tranche Of Private Placement
Brief: Revive Therapeutics Nears Completion Of Key Nerve Agent Countermeasure Study With Canadian Department Of National Defence
Brief: Revive Therapeutics Provides Update On Research Study Evaluating Bucillamine For Nerve Agent Exposure